John G. Cox | Our Leadership | About Us   Next: Richard Brudnick   John G. Cox Chief Executive Officer John G. Cox is our Chief Executive Officer and has served in this position since May 2016. Before his appointment to the role of Bioverativ CEO, John served on the Executive Committee at Biogen as Executive Vice President of Pharmaceutical Operations & Technology, where he oversaw the company’s production facilities, supply chain operations, technical development, quality, and engineering across the globe. He has also had responsibility for the development and commercialization of the company’s biosimilar business and served on the board of Biogen’s biosimilars joint venture, Samsung Bioepis. He also served as interim Executive Vice President, Global Therapeutic Operations, responsible for Biogen’s therapeutic groups of Specialty Medicines and Rare Diseases. This included responsibility for the global commercial performance of the company’s licensed products, which generated over $9 billion in revenues. John joined Biogen in 2003 and held several senior executive positions with the company, including Senior Vice President of Technical Operations, Senior Vice President of Global Manufacturing, and Vice President of Manufacturing and General Manager of Biogen’s operations in Research Triangle Park, North Carolina. He currently serves on the Board of Directors of Repligen Corporation, a life sciences company. John received his B.S. in biology from Arizona State University, M.B.A. from the University of Michigan, and M.S. in cell biology from California State University. John G. Cox | Our Leadership | About Us   Next: Richard Brudnick   John G. Cox Chief Executive Officer John G. Cox is our Chief Executive Officer and has served in this position since May 2016. Before his appointment to the role of Bioverativ CEO, John served on the Executive Committee at Biogen as Executive Vice President of Pharmaceutical Operations & Technology, where he oversaw the company’s production facilities, supply chain operations, technical development, quality, and engineering across the globe. He has also had responsibility for the development and commercialization of the company’s biosimilar business and served on the board of Biogen’s biosimilars joint venture, Samsung Bioepis. He also served as interim Executive Vice President, Global Therapeutic Operations, responsible for Biogen’s therapeutic groups of Specialty Medicines and Rare Diseases. This included responsibility for the global commercial performance of the company’s licensed products, which generated over $9 billion in revenues. John joined Biogen in 2003 and held several senior executive positions with the company, including Senior Vice President of Technical Operations, Senior Vice President of Global Manufacturing, and Vice President of Manufacturing and General Manager of Biogen’s operations in Research Triangle Park, North Carolina. He currently serves on the Board of Directors of Repligen Corporation, a life sciences company. John received his B.S. in biology from Arizona State University, M.B.A. from the University of Michigan, and M.S. in cell biology from California State University.

Management